Controlling distinct signaling states in cultured cancer cells provides a new platform for drug discovery.

Cell Line, Tumor Drug Discovery Gene Expression Profiling Gene Expression Regulation / genetics Glioblastoma / genetics Humans RNA Interference Repressor Proteins / genetics Signal Transduction / genetics
brain tumor drug repurposing glioblastoma glioma signal transduction

Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 31 5 2019
medline: 2 6 2020
entrez: 31 5 2019
Statut: ppublish

Résumé

Cancer cells can switch between signaling pathways to regulate growth under different conditions. In the tumor microenvironment, this likely helps them evade therapies that target specific pathways. We must identify all possible states and utilize them in drug screening programs. One such state is characterized by expression of the transcription factor Hairy and Enhancer of Split 3 (

Identifiants

DOI: 10.1096/fj.201802603RR PMID: 31145643
pubmed: 31145643
doi: 10.1096/fj.201802603RR
doi:

Substances chimiques

HES3 protein, human 0
Repressor Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9235-9249

Subventions

Organisme : Medical Research Council
ID : MR/P010334/1
Pays : United Kingdom

Auteurs

Steven W Poser (SW)

Department of Internal Medicine III, Technische Universität Dresden, Dresden, Germany.

Oliver Otto (O)

Biotechnology Center (BIOTEC), Technische Universität Dresden, Dresden, Germany.

Carina Arps-Forker (C)

Department of Internal Medicine III, Technische Universität Dresden, Dresden, Germany.

Yan Ge (Y)

Biotechnology Center (BIOTEC), Technische Universität Dresden, Dresden, Germany.
Biomedical Cybernetics Group, Department of Physics, Biotechnology Center (BIOTEC), Center for Molecular and Cellular Bioengineering (CMCB), Center for Systems Biology Dresden (CSBD), Technische Universität Dresden, Dresden, Germany.

Maik Herbig (M)

Biotechnology Center (BIOTEC), Technische Universität Dresden, Dresden, Germany.

Cordula Andree (C)

Technology Development Studio, Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany.

Konrad Gruetzmann (K)

Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases (NCT) Dresden, Dresden, Germany; German Cancer Consortium (DKTK), Dresden, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Melissa F Adasme (MF)

Biotechnology Center (BIOTEC), Technische Universität Dresden, Dresden, Germany.

Szymon Stodolak (S)

Division of Cancer and Stem Cells, University of Nottingham, Nottingham, United Kingdom.

Polyxeni Nikolakopoulou (P)

Department of Internal Medicine III, Technische Universität Dresden, Dresden, Germany.

Deric M Park (DM)

Department of Neurology, Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, Illinois, USA.
Innate Repair, London, United Kingdom.

Alan Mcintyre (A)

Division of Cancer and Stem Cells, University of Nottingham, Nottingham, United Kingdom.

Mathias Lesche (M)

Biotechnology Center (BIOTEC), Technische Universität Dresden, Dresden, Germany.
Center for Regenerative Therapies Dresden, Dresden, Germany.

Andreas Dahl (A)

Biotechnology Center (BIOTEC), Technische Universität Dresden, Dresden, Germany.
Center for Regenerative Therapies Dresden, Dresden, Germany.

Petra Lennig (P)

B - CUBE Center for Molecular Bioengineering, Technische Universität Dresden, Dresden, Germany.

Stefan R Bornstein (SR)

Department of Internal Medicine III, Technische Universität Dresden, Dresden, Germany.
Innate Repair, London, United Kingdom.

Evelin Schroeck (E)

Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases (NCT) Dresden, Dresden, Germany; German Cancer Consortium (DKTK), Dresden, Germany.
Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Barbara Klink (B)

Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases (NCT) Dresden, Dresden, Germany; German Cancer Consortium (DKTK), Dresden, Germany.
Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Ronen R Leker (RR)

Stroke Unit, Department of Neurology, Stroke Center and the Peritz and Chantal Sheinberg Cerebrovascular Research Laboratory, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Marc Bickle (M)

Technology Development Studio, Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany.

George P Chrousos (GP)

First Department of Pediatrics, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Aghia Sophia Children's Hospital, Athens, Greece.

Michael Schroeder (M)

Biotechnology Center (BIOTEC), Technische Universität Dresden, Dresden, Germany.

Carlo Vittorio Cannistraci (CV)

Biomedical Cybernetics Group, Department of Physics, Biotechnology Center (BIOTEC), Center for Molecular and Cellular Bioengineering (CMCB), Center for Systems Biology Dresden (CSBD), Technische Universität Dresden, Dresden, Germany.
Brain Bio-Inspired Computing (BBC) Lab, IRCCS Centro Neurolesi Bonino Pulejo, Messina, Italy.

Jochen Guck (J)

Biotechnology Center (BIOTEC), Technische Universität Dresden, Dresden, Germany.

Andreas Androutsellis-Theotokis (A)

Department of Internal Medicine III, Technische Universität Dresden, Dresden, Germany.
Division of Cancer and Stem Cells, University of Nottingham, Nottingham, United Kingdom.
Innate Repair, London, United Kingdom.
Center for Regenerative Therapies Dresden, Dresden, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Controlling distinct signaling states in...
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Découverte de médicament › Controlling distinct signaling states in...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de profil d'expression de gènes › Controlling distinct signaling states in...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Controlling distinct signaling states in...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Astrocytome › Glioblastome › Controlling distinct signaling states in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Controlling distinct signaling states in...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Extinction de l'expression des gènes › Interférence par ARN › Controlling distinct signaling states in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Protéines de répression › Controlling distinct signaling states in...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Controlling distinct signaling states in...